Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 4/20 | 0.72 |
| ▸ | PDE2A | O00408 | 7/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971129 | 0.89 | SLC29A1 (0.62) | NT5EPDE2AADORA2AADORA1ADORA3 | |
| SCHEMBL8971138 | 0.89 | SLC29A1 (0.62) | NT5EPDE2AADORA2AADORA1ADORA3 | |
| SCHEMBL14086557 | 0.84 | PDE2A (0.72) | NT5EPDE2AADORA2AADORA1ADORA3 | |
| SCHEMBL14074362 | 0.84 | PDE2A (0.72) | NT5EPDE2AADORA2AADORA1ADORA3 | |
| SCHEMBL10026376 | 0.84 | PDE2A (0.72) | NT5EPDE2AADORA2AADORA1ADORA3 | |
| SCHEMBL20350734 | 0.84 | PDE2A (0.72) | NT5EPDE2AADORA2AADORA1ADORA3 | |
| SCHEMBL19100898 | 0.84 | NT5E (1.00) | NT5E | |
| SCHEMBL19366686 | 0.84 | NT5E (1.00) | NT5E | |
| SCHEMBL29489832 | 0.83 | ADORA2A (0.67) | NT5EPDE2AADORA2AADORA1ADORA3 | |
| SCHEMBL22807175 | 0.83 | ADORA2A (0.67) | NT5EPDE2AADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3399984-B1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210371449-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2021-12-02 | — | — | US | disclosed |
| US-11001603-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20210002322-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001603-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885PDE2A 142/4885ADORA2A 19/4885 |
| US-20210002322-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885PDE2A 137/4885ADORA2A 19/4885 |
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885PDE2A 137/4885ADORA2A 19/4885 |
| US-20210371449-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | NT5E 3/4885PDE2A 137/4885ADORA2A 19/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885PDE2A 142/4885ADORA2A 19/4885 |
| US-10239912-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | NT5E 3/4885PDE2A 142/4885ADORA2A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.